Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, and Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai National Center for Translational Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, and Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai National Center for Translational Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
J Lipid Res. 2020 Oct;61(10):1320-1327. doi: 10.1194/jlr.RA120000771. Epub 2020 Jul 23.
Lipoprotein (a) [Lp(a)] is a well-known risk factor for cardiovascular disease, but analysis on Lp(a) and renal dysfunction is scarce. We aimed to investigate prospectively the association of serum Lp(a) with the risk of reduced renal function, and further investigated whether diabetic or hypertensive status modified such association. Six thousand two hundred and fifty-seven Chinese adults aged ≤40 years and free of reduced renal function at baseline were included in the study. Reduced renal function was defined as estimated glomerular filtration rate <60 ml/min/1.73 m During a mean follow-up of 4.4 years, 158 participants developed reduced renal function. Each one-unit increase in log-Lp(a) (milligrams per deciliter) was associated with a 1.99-fold (95% CI 1.15-3.43) increased risk of incident reduced renal function; the multivariable-adjusted odds ratio (OR) for the highest tertile of Lp(a) was 1.61 (95% CI 1.03-2.52) compared with the lowest tertile ( for trend = 0.03). The stratified analysis showed the association of serum Lp(a) and incident reduced renal function was more prominent in participants with prevalent diabetes [OR 4.04, 95% CI (1.42-11.54)] or hypertension [OR 2.18, 95% CI (1.22-3.89)]. A stronger association was observed in the group with diabetes and high Lp(a) (>25 mg/dl), indicating a combined effect of diabetes and high Lp(a) on the reduced renal function risk. An elevated Lp(a) level was independently associated with risk of incident reduced renal function, especially in diabetic or hypertensive patients.
脂蛋白 (a) [Lp(a)] 是心血管疾病的一个众所周知的危险因素,但关于 Lp(a) 与肾功能不全的分析却很少。我们旨在前瞻性研究血清 Lp(a) 与肾功能下降风险的关系,并进一步研究糖尿病或高血压状态是否改变了这种关系。
该研究纳入了 6257 名年龄≤40 岁且基线时无肾功能下降的中国成年人。肾功能下降定义为估算肾小球滤过率<60 ml/min/1.73 m2。在平均 4.4 年的随访期间,有 158 名参与者出现了肾功能下降。
每增加一个单位的 log-Lp(a)(毫克/分升),发生肾功能下降的风险就会增加 1.99 倍(95%CI 1.15-3.43);与最低三分位相比,Lp(a) 最高三分位的多变量调整比值比(OR)为 1.61(95%CI 1.03-2.52)(趋势检验=0.03)。分层分析显示,在患有糖尿病[OR 4.04,95%CI(1.42-11.54)]或高血压[OR 2.18,95%CI(1.22-3.89)]的参与者中,血清 Lp(a)与肾功能下降的关联更为显著。在糖尿病和高 Lp(a)(>25mg/dl)的患者中观察到更强的关联,表明糖尿病和高 Lp(a) 对肾功能下降风险有联合作用。
Lp(a) 水平升高与发生肾功能下降的风险独立相关,尤其是在糖尿病或高血压患者中。